GT Metabolic key facts
as of Oct 2026- Developer of a gastrointestinal device system designed to perform a minimally invasive procedure in the field of gastroenterology.
- GT Metabolic is valued at approximately $56.0M as of Oct 2026 (last reported valuation).
- It has raised $46.5M; the latest was Later Stage VC ($27.9M) in Dec 2025.
- Notable investors include HealthTech Capital, Krillion Ventures, AB Medica, Ceros Financial Services.
- Status: Privately Held (backing).
GT Metabolic's last reported valuation, Jan 2023. Nothing priced has surfaced since.
- ·Watch GT Metabolic: the Monday email on marks, rounds and moves
GT Metabolic funding rounds
No funding rounds for GT Metabolic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs GT Metabolic
4GT Metabolic valuation
GT Metabolic's last reported valuation was $56 million in Jan 2023. No priced round, secondary trade or fund mark has surfaced since.
GT Metabolic investors
4 investors are on record for GT Metabolic, including HealthTech Capital, Krillion Ventures, AB Medica and Ceros Financial Services.
About GT Metabolic
Developer of a gastrointestinal device system designed to perform a minimally invasive procedure in the field of gastroenterology. The company's system can be used for medical procedures by creating a magnetic connection in the gastrointestinal tract, enabling medical professionals with a potentially less invasive approach compared to traditional surgical methods.
- Sector
- Healthcare
- HQ
- San Jose, CA, United States
- Founded
- 2020
- Employees
- 19
- Website
- gtmetabolic.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.